Dr. Rosenthal describes the unmet need in frontotemporal dementia and mechanism of action of latozinemab. He covers the trial design and explains why a new co-primary endpoint was recently added to the statistical plan. Plus, developing a similar medicine for early stage Alzheimer's, and how Alector is trying to get therapies across the blood-brain barrier more efficiently.

Founder & CEO Yujiro Hata describes the idea behind precision medicine and synthetic lethality. We discuss the company's pipeline assets Darovasertib, a DLL3 ADC, MAT2A, and more.

Chairman & CEO Sean McCarthy walks us through the science and describes what CytomX has learned about it over many years of working on masking. He discusses the recent EpCAM data, and highlights IFN-α2b and partnered programs.

CEO Jason Coloma walks us through the science that is taking place at the company's South San Francisco headquarters, and descrbies the development programs. The lead program for APOL1-Mediated Kidney Disease is in phase 2, and a second for PKU and Chronic Kidney Disease will have important healthy volunteer proof of concept data this quarter.

President and CEO Jill Milne describes what she believes is the unmet need and profile of Navenibart, and walks us through future anticipated developments. Plus, discussing the company's OX40 antagonist for atopic dermatitis that will have key healthy volunteer proof of concept data in the third quarter of this year.

Founder & CEO Steve Brown, who created CureWise after receiving his own diagnosis of a rare blood cancer, describes his journey and how CureWise is meant to help patients. Its goal is to start with a diversity of opinions from multiple sources and help them converge on a diagnosis.

He discusses the idea behind Syndeio, which focuses on synaptic function and has a lead program in major depressive disorder. Plus, other work he is doing, and Derek's take on the growth and maturity of the biotech ecosystem in Indiana.

CEO Karen Wurster describes the science behind the company, which recently presented proof-of-concept data from human cells at the ADA meeting. Plus, what it is like working from the IBRI in Indianapolis and being an Indiana biotech company.

IBRI CEO Alan Palkowitz descrbies the work that takes place at the IBRI, which includes both the institute's own research and how it acts as an incubator to biotech companies. Plus, the state of biotech in Indiana and what its strengths are here.

Dr. Lamb, a noted expert in neuroscience and Alzheimer's research, introduces us to Stark and describes the investment in people and equipment that has been made here. The institute has two key focuses of 1) modeling Alzheimer's disease and 2) how to expedite research understandings to treat it. Plus, he discusses a company he has co-founded, called Monument Biosciences, that is focusing on the neuroinflamatory side of the disease.